BIOMAT Database Logo BIOMAT Database Logo

[Recent progress and prospect in oligonucleotide therapeutics]. 2015

Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota

Remarkable progress has been made in chemical modification and nonviral delivery systems that improve the properties and efficacy of therapeutics oligonucleotides therapeutics, such as antisense oligonucleotide (ASO) and small interfering RNA(siRNA). ASOs act through various mechanisms including the degradation of mRNA by RNase H (gapmer-type ASO) and the modulation alternative splicing patterns(splice switching oligonucleotide). Recent favorable outcomes in clinical trials for cancers and genetic diseases such as familial amyloid polyneuropathy and Duchenne muscular dystrophy indicate high clinical potency of oligonucleotide therapeutics. Here we reviewed recent advances in basic properties and clinical applications of ASO and siRNA, and provide future perspective on oligonucleotide therapeutics.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D012106 Research Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed) Research Priorities,Laboratory Research,Research Activities,Research and Development,Activities, Research,Activity, Research,Development and Research,Priorities, Research,Priority, Research,Research Activity,Research Priority,Research, Laboratory
D005544 Forecasting The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology. Futurology,Projections and Predictions,Future,Predictions and Projections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D016376 Oligonucleotides, Antisense Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize. Anti-Sense Oligonucleotide,Antisense Oligonucleotide,Antisense Oligonucleotides,Anti-Sense Oligonucleotides,Anti Sense Oligonucleotide,Anti Sense Oligonucleotides,Oligonucleotide, Anti-Sense,Oligonucleotide, Antisense,Oligonucleotides, Anti-Sense
D034741 RNA, Small Interfering Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions. RNA, Scan,Repeat-Associated siRNA,Scan RNA,Small Scan RNA,Trans-Acting siRNA,siRNA,siRNA, Repeat-Associated,siRNA, Trans-Acting,Short Hairpin RNA,Short Interfering RNA,Small Hairpin RNA,Small Interfering RNA,scnRNA,shRNA,tasiRNA,Hairpin RNA, Short,Hairpin RNA, Small,Interfering RNA, Short,Interfering RNA, Small,RNA, Short Hairpin,RNA, Short Interfering,RNA, Small Hairpin,RNA, Small Scan,Repeat Associated siRNA,Scan RNA, Small,Trans Acting siRNA,siRNA, Repeat Associated,siRNA, Trans Acting

Related Publications

Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Recent progress in oligonucleotide therapeutics: antisense to aptamers.
September 2008, Expert opinion on drug discovery,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Progress in antisense oligonucleotide therapeutics.
January 1996, Annual review of pharmacology and toxicology,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Recent progress in therapeutics.
October 1950, Journal of the Indian Medical Association,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Recent progress in oligonucleotide synthesis.
January 1996, Acta biochimica Polonica,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Recent progress in oligonucleotide synthesis.
January 1980, Nucleic acids symposium series,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
January 2015, Future medicinal chemistry,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
April 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Recent Advances in Oligonucleotide Therapeutics in Oncology.
March 2021, International journal of molecular sciences,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
Recent Developments in Oligonucleotide Based Therapeutics. Preface.
June 2015, Advanced drug delivery reviews,
Kotaro Yoshioka, and Hiroya Kuwahara, and Kazutaka Nishina, and Tetsuya Nagata, and Takanori Yokota
[Recent progress and prospect of knee replacement].
September 2012, Zhonghua yi xue za zhi,
Copied contents to your clipboard!